 The FDA has informed Rigel Pharmaceuticals Inc NASDAQ: RIGL that data submitted in May from fostamatinib Phase 2 trial for COVID-19 is insufficient for an emergency use authorization EUA. Rigel submitted clinical data from a 59-patient NIHNHLBI-sponsored Phase 2 trial of fostamatinib for hospitalized COVID-19 patients. 